MB-272

N/A

Report date: 2023/09/13 20:27:13

Base Information

Drug NameMB-272
Drug Alias NameMB272GS-0272
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionB- and T-lymphocyte attenuator agonists
TargetsB- and T-lymphocyte attenuator
Therapy Area/IndicationsAutoimmune DiseasesArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGeorgiaUnited Kingdom +[4] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of OxfordMiroBio Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGilead Sciences IncMiroBio Ltd
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A